An information explosion on the numbers and mechanisms of functional RNAs has spurred oligonucleotide-based therapeutic development. Pharmas and big biotechs are carving up the space via partnerships, adding multiple nucleic acid-based technologies to their drug discovery toolboxes. The newest kids on the block are noncoding RNAs such as microRNAs and long noncoding RNAs, which can selectively turn on expression of a given gene and thus achieve therapeutic outcomes that no other drug platform can.